A61K 47/646
The entire peptide or protein drug conjugate elicits an immune response
Official title: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
A61K47/646 (The entire peptide or protein drug conjugate elicits an immune response) appears on 984 US grants and 1,496 published applications in this corpus.
Search patents in A61K- Granted patents
- 984
- Published applications
- 1,496
- Assignees
- 673
- Inventors
- 2,373
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 6 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 3 | 0 |
| 1990 | 3 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 5 | 0 |
| 1994 | 7 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 14 | 0 |
| 1998 | 20 | 0 |
| 1999 | 14 | 0 |
| 2000 | 15 | 0 |
| 2001 | 20 | 1 |
| 2002 | 20 | 23 |
| 2003 | 18 | 44 |
| 2004 | 10 | 40 |
| 2005 | 12 | 47 |
| 2006 | 20 | 48 |
| 2007 | 13 | 36 |
| 2008 | 9 | 45 |
| 2009 | 17 | 49 |
| 2010 | 17 | 59 |
| 2011 | 33 | 64 |
| 2012 | 24 | 61 |
| 2013 | 30 | 48 |
| 2014 | 48 | 72 |
| 2015 | 62 | 96 |
| 2016 | 52 | 65 |
| 2017 | 45 | 55 |
| 2018 | 59 | 84 |
| 2019 | 52 | 68 |
| 2020 | 65 | 101 |
| 2021 | 50 | 81 |
| 2022 | 42 | 76 |
| 2023 | 60 | 67 |
| 2024 | 39 | 70 |
| 2025 | 43 | 62 |
| 2026 | 19 | 34 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines11 Aug 2026US 12,702,705 B2Glaxosmithkline Biologicals SA
- Monoclonal antibody and vaccine targeting filamentous bacteriophage23 Jun 2026US 12,661,411 B2Inimmune Corporation
- Immunotherapeutic for prostate cancer treatment9 Jun 2026US 12,648,985 B2Hexamer Therapeutics, Inc.
- Complexes for delivery of antigenic peptides9 Jun 2026US 12,649,001 B2The Regents of the University of Michigan
- Self-assembling nanoparticles2 Jun 2026US 12,642,851 B2Barinthus Biotherapeutics North America, Inc.
- Polypeptide adjuvants and uses thereof24 Sep 2026US 2026/0284209 A1Board of Regents, The University of Texas System
- Antibiotic Vancomycin-Teixobactin Conjugates10 Sep 2026US 2026/0263611 A1The Regents of the University of California
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Immunogenic Composition20 Aug 2026US 2026/0240990 A1Glaxosmithkline Biologicals SA
- Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof6 Aug 2026US 2026/0224683 A1Pfizer Inc.
Most cited
By later US patents
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- Receptor specific transepithelial transport of therapeutics214US 6,030,613 ABrandeis University · 2000
- Receptor specific transepithelial transport of immunogens207US 6,086,875 ABrandeis University · 2000
- Multiple cytokine protein complexes145US 6,617,135 B1EMD Lexigen Research Center Corp. · 2003
- Recombinant toxin fragments113US 6,461,617 B1Microbiological Research Authority · 2002